#EXP00152

General

Accession EXP00152
Activity Formation (3-24h)
Date 2013-11-26
Administration In solution
Model in vitro
Organism Pseudomonas aeruginosa
Status Validated
Notes Pa9 clinical isolate

Peptide

SMAP-29

RGLRRLGRKIAHGVKKYGPTVLRIIRIA

Experimental activity

Method Concentration Notes
Crystal violet assay 1.251 uM No notes
Crystal violet assay 0.626 uM No notes

References

Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients

A. Pompilio, M. Scocchi, S. Pomponio, F. Guida, A. Di Primio, E. Fiscarelli, R. Gennaro, G. Di Bonaventura

2011. Peptides 9:1807-1814